Douglas J. Swirsky's Insider Trades & SAST Disclosures
Douglas J. Swirsky's most recent trade in MaxCyte Inc was a trade of 150,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Douglas J. Swirsky.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| MaxCyte Inc | Douglas J Swirsky | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| MaxCyte Inc | Douglas J Swirsky | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 37,500 | 118,750 | - | 0 | Common Stock | |
| Cellectar Biosciences Inc | Douglas J Swirsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 90,000 | 90,000 | - | - | Stock option (right to buy) | |
| Cellectar Biosciences Inc | Douglas J Swirsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 90,000 | 90,000 | - | - | Stock option (right to buy) | |
| MaxCyte Inc | Douglas J Swirsky | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 225,000 | 225,000 | - | - | Employee Stock Option (right to buy) | |
| MaxCyte Inc | Douglas J Swirsky | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 81,250 | 81,250 | - | 0 | Common Stock | |
| Cellectar Biosciences Inc | Douglas J Swirsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 37,500 | 71,925 | - | - | Stock option (right to buy) | |
| Cellectar Biosciences Inc | Douglas J. Swirsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 11,700 | 11,700 | - | - | Stock option (right to buy) | |
| Cellectar Biosciences Inc | Douglas J. Swirsky | Director | Purchase of securities on an exchange or from another person at price $ 1.04 per share. | 14 Sep 2021 | 25,000 | 25,000 (0%) | 0% | 1.0 | 26,000 | Common Stock |
| Cellectar Biosciences Inc | Douglas J. Swirsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 117,000 | 117,000 | - | - | Stock option (right to buy) | |
| MetaVia Inc. | Douglas J. Swirsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2020 | 60,000 | 60,000 | - | - | Non-qualified stock option (right to buy) | |
| Cellectar Biosciences Inc | Douglas J. Swirsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 80,000 | 80,000 | - | - | Stock option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges